CYP2A6 Effects on Subjective Reactions to Initial Smoking Attempt

被引:2
|
作者
Cannon, Dale S. [1 ]
Mermelstein, Robin J. [2 ,3 ]
Medina, Tait R. [4 ]
Pugach, Oksana [4 ]
Hedeker, Donald [5 ]
Weiss, Robert B. [6 ]
机构
[1] Univ Utah, Sch Med, Dept Psychiat, 650 Komas Dr,Suite 206, Salt Lake City, UT 84108 USA
[2] Univ Illinois, Inst Hlth Res, Chicago, IL USA
[3] Univ Illinois, Policy & Psychol Dept, Chicago, IL USA
[4] Univ Illinois, Inst Publ Hlth Res & Policy, Chicago, IL USA
[5] Univ Chicago, Dept Hlth Sci, Chicago, IL 60637 USA
[6] Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84108 USA
基金
美国国家卫生研究院;
关键词
NICOTINE DEPENDENCE; TOBACCO DEPENDENCE; SMOKERS; ASSOCIATION; ADDICTION; BEHAVIOR; GENES; RISK; ADOLESCENTS; METABOLISM;
D O I
10.1093/ntr/ntv244
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Introduction: In very novice smokers, CYP2A6 genotypes that reduce nicotine metabolism to an intermediate rate may increase smoking risk, relative to both normal and slow rates. The present study examined the hypothesis that intermediate metabolism variants are associated with greater pleasurable effects of the initial smoking attempt than either normal or slow metabolism variants. Methods: Participants were novice smokers (N = 261, 65% female) of European descent. Predicted nicotine metabolic rate based on CYP2A6 diplotypes (CYP2A6 Diplotype Predicted Rate [CDPR]) was partitioned into Normal, Intermediate, and Slow categories using a metabolism metric. Subjective reactions to the initial smoking attempt were assessed by the Pleasurable Smoking Experiences (PSE) scale, which was collected within 3 years of the initial smoking attempt. The effect of CDPR on PSE was tested using a generalized linear model in which CDPR was dummy coded and Intermediate CDPR was the reference condition. Gender was included in the model as a control for higher PSE scores by males. Results: Lower PSE scores were associated with Normal CDPR, beta = -0.34, P =.008, and Slow CDPR, beta = -0.52, P =.001, relative to Intermediate CDPR. Conclusions: Intermediate CDPR-enhanced pleasurable effects of the initial smoking attempt relative to other CYP2A6 variants. This finding is consistent with the hypothesis that the risk effect of Intermediate CDPR on early smoking is a function of optimal pleasurable effects. Implications: This study supports our recent hypothesis that CYP2A6 diplotypes that encode intermediate nicotine metabolism rate are associated with enhanced pleasurable events following the initial smoking attempt, compared with diplotypes that encode either normal or slow metabolism. This hypothesis was offered to account for our unexpected previous finding of enhanced smoking risk in very novice smokers associated with intermediate metabolism rate. Our new finding encourages further investigation of time-dependent relations between CYP2A6 effects and smoking motives, and it encourages laboratory study of the mechanisms underlying the initial smoking enhancement in novice smokers associated with intermediate metabolism.
引用
收藏
页码:637 / 641
页数:5
相关论文
共 50 条
  • [31] Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C
    Ariyoshi, N
    Takahashi, Y
    Miyamoto, M
    Umetsu, Y
    Daigo, S
    Tateishi, T
    Kobayashi, S
    Mizorogi, Y
    Loriot, MA
    Stücker, I
    Beaune, P
    Kinoshita, M
    Kamataki, T
    PHARMACOGENETICS, 2000, 10 (08): : 687 - 693
  • [32] Association between CYP2A6 genotypes and smoking behavior in Lebanese smokers
    Farra, Chantal
    Assaf, Nada
    Karaky, Nathalie
    Diab, Sara
    Zaatari, Ghazi
    Cortas, Najwa
    Daher, Rose T.
    META GENE, 2020, 23
  • [33] Inhibitory Potency of 8-Methoxypsoralen on Cytochrome P450 2A6 (CYP2A6) Allelic Variants CYP2A6*15, CYP2A6*16, CYP2A6*21 and CYP2A6*22: Differential Susceptibility Due to Different Sequence Locations of the Mutations
    Tiong, Kai Hung
    Yunus, Nafees Ahemad Mohammed
    Yiap, Beow Chin
    Tan, Eng Lai
    Ismail, Rusli
    Ong, Chin Eng
    PLOS ONE, 2014, 9 (01):
  • [34] Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence
    Malaiyandi, V
    Sellers, EM
    Tyndale, RF
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (03) : 145 - 158
  • [35] A meta-analytic review of the CYP2A6 genotype and smoking behavior
    Carter, BL
    Long, TY
    Cinciripini, PM
    NICOTINE & TOBACCO RESEARCH, 2004, 6 (02) : 221 - 227
  • [36] CORRELATION OF CYP2A6 ENZYME ACTIVITY WITH GENOTYPE AND CIGARETTE SMOKING IN SERBS
    Djordjevic, N.
    Carrillo, J. A.
    Gervasini, G.
    Jankovic, S.
    Aklillu, E.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 21 - 22
  • [37] CYP2A6 phenotype in a Spanish population:: Influence of gender, age and smoking
    Carcas de Benavides, C.
    Fanlo Villacampa, A.
    Soriano Guillén, A.
    Vicente Romero, J.
    Arenaz Villalba, I.
    Mayayo Dehesa, E.
    Sinués Porta, B.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 99 : 53 - 54
  • [38] A CYP2A6 haplotype explains a substantial part of CYP2A6 phenotype variation in caucasians
    Haberl, M
    Weil, R
    Fuss, C
    Zanger, UM
    Kerb, R
    Wojnowski, L
    DRUG METABOLISM REVIEWS, 2003, 35 : 67 - 67
  • [39] PharmVar GeneFocus: CYP2A6
    Langlois, Alec W. R.
    Chenoweth, Meghan J.
    Twesigomwe, David
    Scantamburlo, Giada
    Whirl-Carrillo, Michelle
    Sangkuhl, Katrin
    Klein, Teri E.
    Nofziger, Charity
    Tyndale, Rachel F.
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (04) : 948 - 962
  • [40] Inhibitory effects of neurotransmitters and steroids on human CYP2A6
    Higashi, Eriko
    Nakajima, Miki
    Katoh, Miki
    Tokudome, Shogo
    Yokoi, Tsuyoshi
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (04) : 508 - 514